Creative Planning
TRDA icon

Creative Planning’s Entrada Therapeutics TRDA Stock Holding History

Creative Planning’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,230
Closed -$281K – 4400
2026
Q1 		$281K Buy
22,230
+148
+0.7% +$1.7K ﹤0.01% 3476
2025
Q4 		$227K Buy
+22,082
New +$186K ﹤0.01% 3455
2025
Q2 		– Sell
-14,443
Closed -$131K – 3791
2025
Q1 		$131K Buy
+14,443
New +$180K ﹤0.01% 3198

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Creative Planning's TRDA Position: Q2 2026 in Review

Creative Planning sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 22,230 shares — an estimated $281K sold.

Creative Planning first reported a position in TRDA in Q1 2025 and held it in 3 quarters. The position peaked at $281K in Q1 2026. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Creative Planning reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Creative Planning sold 22,230 Entrada Therapeutics shares in Q2 2026, an estimated $281K.
  • Creative Planning first reported a position in Entrada Therapeutics in Q1 2025 and held it in 3 quarters.
  • Creative Planning's Entrada Therapeutics position peaked at $281K in Q1 2026.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.